
SKIN Stock Forecast & Price Target
SKIN Analyst Ratings
Bulls say
SkinHealth Systems is positioned for improvement because management is attacking its main growth bottleneck in Delivery Systems through better sales-force execution, corporate account expansion, and a new U.S. rental program that should reduce provider financing friction and support installed-base growth. Its core strength remains the recurring consumables franchise, which returned to +1.2% growth in 3Q, accounted for 73% of revenue in 2Q26, and benefits from launches like HydraScalp, SkinStylus growth of 39% in 3Q, and a 36,516-system installed base. Even with continued EMEA weakness and competitive pressure, profitability is improving materially, with 3Q revenue of $69.2mm, gross margin of 71.8%, and adjusted EBITDA margin of 19.3%, while upcoming 2027 and 2028 product catalysts add longer-term upside.
Bears say
SkinHealth Systems is facing a deteriorating fundamental setup because Delivery Systems sales remain weak, falling -9.6% y/y to $18.8mm and -18% y/y in 2Q, while installed-base productivity is poor, with 770 placements yielding only 97 net additions. The recently launched U.S. rental program may ease provider financing barriers, but adoption is early and was not a meaningful contributor to 3Q, leaving utilization, consumables demand, and provider loyalty pressured amid ongoing Syndeo execution risk. With FY26 revenue guidance lowered, 3Q26 revenue expected at $65-70MM and adj. EBITDA at $5-7MM, and a $250MM November 2028 convertible maturity looming, visibility into a sustained recovery remains limited.
This aggregate rating is based on analysts' research of SkinHealth Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
SKIN Analyst Forecast & Price Prediction
Start investing in SKIN
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About SkinHealth Systems Inc (SKIN) Forecast
SKIN Analyst Forecast & Price Prediction
Start investing in SKIN
Order type
Buy in
Order amount
Est. shares
0 shares